Thrombotic Thrombocytopenic Purpura Market to Reach US$ 1.85 Billion by 2033 at 4.5% CAGR, Driven by Rising Rare Disease Awareness and Caplacizumab Adoption | DataM Intelligence

According to DataM Intelligence, the global Thrombotic Thrombocytopenic Purpura (TTP) market size reached US$ 1.25 billion in 2024 and is expected to reach US$ 1.85 billion by 2033, growing at a CAGR of 4.5% during 2025-2033, driven by increasing diagnosis rates of acquired and inherited TTP, strong adoption of plasma exchange and caplacizumab therapies, growing use of rituximab and corticosteroids, expanding specialty clinic infrastructure, and rising investments in rare hematologic disorder treatments in North America and Asia-Pacific.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/thrombotic-thrombocytopenic-purpura-market?jd

Key Mergers and Acquisitions
✦ January 2026: Takeda Pharmaceutical Company Limited acquired a rare hematology biotech startup to bolster its pipeline of next-generation therapies for acquired TTP and complement its existing caplacizumab offerings.
✦ December 2025: Sanofi completed a strategic licensing deal with a biotech firm developing novel anti-von Willebrand factor agents to strengthen its TTP treatment portfolio beyond plasma exchange and rituximab.
✦ November 2025: Roche (F. Hoffmann-La Roche Ltd) secured an agreement to acquire rights to an investigational complement inhibitor for potential use in refractory TTP cases, expanding its rare disease focus.

Key Industry Developments
☑️ January 2026: Takeda Pharmaceutical Company Limited and Sanofi expanded patient access programs for caplacizumab and rituximab in acquired TTP, with new real-world evidence presented at ASH 2025 supporting earlier intervention in high-risk patients.
☑️ December 2025: Pfizer Inc. and Fresenius Kabi USA, LLC advanced biosimilar rituximab formulations for TTP, gaining additional regulatory approvals in North America and Europe for cost-effective plasma exchange adjunct therapy.
☑️ November 2025: Hikma Pharmaceuticals PLC and Teva Pharmaceutical Industries Ltd. increased supply of corticosteroids and supportive care drugs for TTP management, targeting specialty clinics and hospitals amid rising case volumes.

Purchase the report to unlock market insights:
https://www.datamintelligence.com/buy-now-page?report=thrombotic-thrombocytopenic-purpura-market

Market Segmentation Analysis
By Type: Acquired TTP holds the largest share due to higher prevalence linked to autoimmune triggers and secondary conditions, with strong treatment focus on plasma exchange and caplacizumab; Inherited TTP (congenital) grows steadily with targeted therapies for ADAMTS13 deficiency and lifelong management needs.

By Treatment: Plasma Exchange dominates as the first-line standard for rapid ADAMTS13 activity restoration in acute TTP; Caplacizumab grows fastest for its anti-vWF mechanism reducing platelet consumption; Rituximab and Corticosteroids remain key for immune-mediated cases; Others include emerging complement inhibitors and supportive care.

By End User: Hospitals lead with the highest share due to need for urgent plasma exchange and intensive monitoring in acute TTP episodes; Specialty Clinics grow rapidly for long-term follow-up, rituximab infusions, and caplacizumab administration; Others include home care for stable inherited TTP patients and outpatient infusion centers.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/thrombotic-thrombocytopenic-purpura-market?jd

Competitive Landscape / Key Players
✦ Takeda Pharmaceutical Company Limited - In January 2026, acquired a rare hematology biotech to expand its TTP pipeline and enhance caplacizumab access programs, while presenting new real-world data at ASH 2025 supporting earlier use in high-risk acquired TTP.
✦ Sanofi - Licensed a novel anti-vWF agent in December 2025 for potential refractory TTP, complementing its existing rituximab and plasma exchange ecosystem, with ongoing Phase 2 trials planned for 2026.
✦ Pfizer Inc. - Advanced biosimilar rituximab approvals in December 2025 for TTP adjunct therapy, increasing affordability and access in North America and Europe for immune-mediated cases.
✦ F. Hoffmann-La Roche Ltd - Acquired rights to a complement inhibitor in November 2025 for investigational use in refractory TTP, building on its rare disease portfolio with planned clinical expansion.
✦ Sandoz Group AG - Expanded biosimilar rituximab supply in late 2025 for TTP treatment, focusing on cost-effective alternatives in specialty clinics and hospitals globally.

Regional Insights
North America dominates the TTP market with 43.5% revenue share in 2024, supported by high diagnosis rates of acquired TTP, rapid FDA approvals (e.g., caplacizumab), advanced hematology care infrastructure, strong reimbursement for plasma exchange and biologics, and significant R&D investment in stage 4 fibrosis and complement pathways.

Asia-Pacific is the fastest-growing region at 8.1% CAGR, fueled by rising metabolic syndrome and autoimmune disease burden, increasing awareness and diagnosis of TTP, expanding specialty clinics and hospital infrastructure, government initiatives for rare disease treatment access, and growing clinical trial participation by global players.

Unlock 360° Market Intelligence with DataM Intelligence Subscription Services:
https://www.datamintelligence.com/reports-subscription?jd

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.